Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1830 in Warm Autoimmune Hemolytic Anemia
NCT04256148Phase 2Withdrawn
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of orilanolimab in warm autoimmune hemolytic anemia (wAIHA), sponsored by Alexion Pharmaceuticals. Planned start Jul 2021; status: withdrawn.
02
Drugs
orilanolimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT04256148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256148.